EDARAVONE Drug Patent Profile

When do Edaravone patents expire, and what generic alternatives are available?

Edaravone is a drug marketed by Dr Reddys, Gland, Hikma, Long Grove Pharms, Pharmobedient, Sandoz, and Zydus Pharms. and is included in seven NDAs.

The generic ingredient in EDARAVONE is edaravone. There is one drug master file entry for this compound. Four suppliers are listed for this compound. Additional details are available on the edaravone profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Edaravone

A generic version of EDARAVONE was approved as edaravone by GLAND on May 6^th, 2024.

Summary for EDARAVONE

US Patents:	0
Applicants:	7
NDAs:	7
Finished Product Suppliers / Packagers:	3
Raw Ingredient (Bulk) Api Vendors:	117
Clinical Trials:	66
Patent Applications:	3,388
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for EDARAVONE
DailyMed Link:	EDARAVONE at DailyMed

Recent Clinical Trials for EDARAVONE

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Prilenia	PHASE3
Ferrer Internacional S.A.	PHASE3
Jiangsu Chia Tai Fenghai Pharmaceutical Co., Ltd.	PHASE2

See all EDARAVONE clinical trials

Anatomical Therapeutic Chemical (ATC) Classes for EDARAVONE

N07XX	Other nervous system drugs
N07X	OTHER NERVOUS SYSTEM DRUGS
N07	OTHER NERVOUS SYSTEM DRUGS
N	Nervous system

Paragraph IV (Patent) Challenges for EDARAVONE

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
RADICAVA ORS	Oral Suspension	edaravone	105 mg/5 mL	215446	1	2023-04-20

US Patents and Regulatory Information for EDARAVONE

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Dr Reddys	EDARAVONE	edaravone	SOLUTION;INTRAVENOUS	215917-001	May 6, 2024		DISCN	No	No
Pharmobedient	EDARAVONE	edaravone	SOLUTION;INTRAVENOUS	217565-002	Oct 31, 2024		DISCN	No	No
Hikma	EDARAVONE	edaravone	SOLUTION;INTRAVENOUS	215508-001	May 6, 2024	AP	RX	No	No
Sandoz	EDARAVONE	edaravone	SOLUTION;INTRAVENOUS	216902-001	Dec 23, 2024	AP	RX	No	No
Gland	EDARAVONE	edaravone	SOLUTION;INTRAVENOUS	216199-001	May 6, 2024	AP	RX	No	Yes
Gland	EDARAVONE	edaravone	SOLUTION;INTRAVENOUS	216199-002	May 6, 2024		DISCN	No	No
Pharmobedient	EDARAVONE	edaravone	SOLUTION;INTRAVENOUS	217565-001	Oct 31, 2024		DISCN	No	No

Edaravone Market Dynamics, Revenue Outlook, Patents, and Competitive Landscape

Last updated: September 26, 2026

Edaravone is an established neuroprotective drug with two commercial positions: intravenous Radicava and oral suspension Radicava ORS, both marketed by Mitsubishi Tanabe Pharma in the United States for amyotrophic lateral sclerosis (ALS). The U.S. oral formulation expanded access and reduced infusion burden, but the market remains concentrated, dependent on ALS diagnosis and reimbursement, and exposed to generic and alternative-treatment competition.

The commercial outlook is stable rather than high-growth. Revenue depends on converting intravenous patients to oral therapy, maintaining payer coverage, expanding diagnosis and treatment rates, and defending formulation and regulatory exclusivity. Tofersen, riluzole, and investigational ALS therapies create clinical competition, although no approved product directly replaces edaravone across the broad ALS population.

What is edaravone and how is it marketed?

Edaravone is a free-radical scavenger developed for neurodegenerative disease. Mitsubishi Tanabe markets it under the Radicava brand in the United States and Radicut in Japan and other markets.

Product	Active ingredient	Route	U.S. approval	Primary indication	Commercial status
Radicava	Edaravone	Intravenous infusion	May 2017	ALS	Commercial
Radicava ORS	Edaravone oral suspension	Oral	May 2022	ALS	Commercial
Radicut	Edaravone	Intravenous and oral formulations in certain markets	Earlier approvals outside the U.S.	ALS and other country-specific indications	Commercial outside the U.S.

The original U.S. approval was based on a controlled study in patients with relatively early ALS and preserved function. The treatment effect was measured primarily through the ALS Functional Rating Scale-Revised, or ALSFRS-R. The FDA label identifies a treatment schedule of daily dosing for 14 days followed by 14 days off during the first cycle, then 10 days of dosing within 14-day cycles for subsequent cycles. [1]

Radicava ORS uses the same active ingredient but changes administration from infusion to oral dosing. This matters commercially because infusion-site capacity, nursing support, travel, and patient time affect treatment persistence.

How large is the edaravone market?

The addressable market is the treated ALS population rather than the entire ALS prevalence pool. ALS prevalence in the United States is generally estimated at roughly 16,000 to 32,000 people, with annual incidence of approximately 5,000 cases, although estimates vary by methodology and case ascertainment. [2]

Market revenue is influenced by four variables:

1. The number of diagnosed ALS patients.
2. The percentage receiving disease-modifying treatment.
3. Persistence on edaravone.
4. Net price after rebates, discounts, government programs, and site-of-care costs.

Mitsubishi Tanabe has not consistently disclosed Radicava revenue as a separate global line in all reporting periods. Public company reporting groups products within broader business segments, which limits precise independent verification of worldwide edaravone sales. The U.S. franchise remains commercially important because U.S. pricing is substantially higher than pricing in Japan and many other markets.

A practical market model is:

Driver	Effect on edaravone revenue
Oral formulation adoption	Increases addressable patients and reduces infusion friction
Earlier diagnosis	Expands the eligible treatment pool
Long treatment duration	Raises annual revenue per treated patient
Payer restrictions	Reduces initiation and can delay therapy
Generic IV entry	Pressures infusion product pricing
Oral formulation patents or exclusivity	May delay substitution for Radicava ORS
New ALS therapies	Could reduce share of eligible patients or combination-treatment demand

The principal growth opportunity is not a large expansion in ALS prevalence. It is greater penetration within the diagnosed and treated population.

What is the financial trajectory for edaravone?

Edaravone revenue initially rose after the 2017 U.S. approval because it created a branded ALS franchise in a market with limited disease-modifying options. The launch of Radicava ORS in 2022 changed the product’s commercial profile by allowing home administration and reducing reliance on infusion centers.

Financial trajectory by phase

Period	Commercial event	Financial effect
Before 2017	Japan-led edaravone sales	Established product and manufacturing base
2017-2021	U.S. intravenous Radicava launch	Rapid expansion of global branded revenue
2022-2023	U.S. oral suspension launch	New patient access and conversion opportunity
2024 onward	Portfolio maturation	Growth depends on oral penetration, persistence, and exclusivity
Post-exclusivity period	Generic and formulation competition	Likely net-price and market-share pressure

The oral product can support revenue even if total ALS patient numbers remain flat. A patient who declines repeated infusions may accept oral treatment, and an infusion patient may remain on therapy longer because administration is easier. The offset is potential cannibalization of higher-priced or higher-margin infusion revenue.

The key commercial question is whether oral adoption is incremental or primarily a route-of-administration switch. If most oral prescriptions replace intravenous prescriptions, volume may rise while the product mix shifts. If oral therapy reaches previously untreated patients, the franchise can achieve both volume and revenue expansion.

What patents protect edaravone and Radicava?

Edaravone is an old active ingredient, so basic composition-of-matter protection is no longer the primary barrier to competition. The relevant protection is more likely to involve formulation, dosing, oral delivery, manufacturing, and method-of-use claims.

The United States has separate intellectual-property questions for intravenous edaravone and oral edaravone suspension:

Protection category	IV Radicava	Radicava ORS
Active ingredient	Generally mature and vulnerable to generic competition	Same underlying active ingredient
Formulation	Solution, concentration, stability, container and administration claims may matter	Suspension, excipients, particle properties, stability, and dosing claims may matter
Method of use	ALS treatment and dosing regimens	ALS treatment and oral dosing regimens
Manufacturing	Purity, stability, scale-up, and product consistency	More relevant because suspension uniformity and stability affect product quality
Regulatory exclusivity	Historically significant at launch	Newer formulation-related exclusivity may have been relevant after approval
Trade secrets	Manufacturing and quality-control processes	Potentially material for suspension manufacture and release testing

The U.S. Orange Book is the controlling source for patents listed against an approved small-molecule product. FDA Orange Book listings can change through patent expiration, delisting, corrections, or new submissions. A transaction or litigation analysis should distinguish patents listed for Radicava ORS from patents associated with the older intravenous formulation. [3]

No widely reported, market-defining Paragraph IV litigation against Radicava had established a generic launch date through the principal public sources used for this analysis. That does not eliminate litigation risk. It means that the commercial threat is more likely to arise from future ANDA filings, product-specific patent challenges, or non-infringing alternative formulations.

When does edaravone lose exclusivity?

Edaravone’s exclusivity is product-specific. The active ingredient’s age does not establish the date on which every Radicava formulation becomes substitutable.

U.S. regulatory exclusivity

Radicava received FDA approval in 2017. Radicava ORS was approved in 2022. Small-molecule products may receive five years of new chemical entity exclusivity, three years of approval-based exclusivity for certain new clinical investigations, and pediatric exclusivity when applicable. [4]

For the oral product, the central commercial protection is likely to be patent and formulation protection rather than a long remaining period of new chemical entity exclusivity, because edaravone itself was previously approved. Exact market exclusivity must be determined from FDA’s current approval and Orange Book records.

Patent expiration

Patent expiration dates can differ by patent family, terminal disclaimers, patent-term adjustment, and pediatric extension. A formulation patent may expire years after the active ingredient’s original protection. The relevant launch scenario is therefore:

• Intravenous generic entry may occur before oral suspension substitution.
• Oral generic entry may require a separate formulation strategy.
• A generic manufacturer may challenge listed patents before expiration through Paragraph IV certification.
• A patent settlement could delay launch without a court decision on validity.

What is the Orange Book status of Radicava?

Radicava and Radicava ORS are FDA-approved prescription products. The Orange Book determines whether FDA lists patents against the products and whether those patents carry pediatric exclusivity or other relevant status.

For commercial diligence, the important distinction is between:

• Drug substance patents, which are unlikely to provide meaningful remaining protection for an old active ingredient.
• Drug product patents, which can cover the IV solution or oral suspension.
• Method-of-use patents, which may cover ALS treatment or dosing.
• Label scope, which determines whether a generic can obtain approval for all or only part of the branded indication.

An ANDA applicant can seek approval with Paragraph IV certification against listed patents. If the brand owner sues within the statutory period, FDA approval may be subject to a 30-month stay, subject to litigation developments and statutory exceptions. [5]

Which companies are challenging edaravone?

The competitive field includes generic pharmaceutical companies, ALS drug developers, and companies developing therapies for genetically defined disease.

Generic manufacturers

Potential generic competitors can pursue:

• IV edaravone solution.
• Oral edaravone suspension.
• Alternative oral dosage forms, if legally and regulatorily viable.
• Limited-label products that omit patented uses.

The IV product is technically more accessible than oral suspension because oral suspensions require control of particle distribution, dose uniformity, stability, and container performance. The technical burden may slow direct substitution even if active-ingredient patents are expired.

ALS drug companies

Biogen markets tofersen, branded Qalsody, for ALS associated with SOD1 mutations. Tofersen is a genetically targeted antisense oligonucleotide and competes for treatment budgets and clinical attention, but it addresses a small molecularly defined subgroup. [6]

Riluzole remains a broad ALS treatment and is available in tablets, oral suspension, and orally disintegrating forms. It is generally lower priced and widely used. Riluzole competes with edaravone on affordability, convenience, and physician familiarity.

Other investigational programs may compete for newly diagnosed patients, but clinical-stage assets do not create immediate commercial substitution unless they produce approval, reimbursement, and demonstrated adoption.

How does edaravone compare with riluzole and tofersen?

Attribute	Edaravone	Riluzole	Tofersen
Brand examples	Radicava, Radicut	Rilutek, Tiglutik, Exservan and generics	Qalsody
Mechanism	Free-radical scavenging and oxidative-stress reduction	Glutamatergic and sodium-channel effects	Antisense therapy targeting SOD1 mRNA
Population	Broad ALS population under label	Broad ALS population	SOD1 mutation-associated ALS
Administration	IV or oral suspension	Oral formulations	Intrathecal administration
Generic pressure	Higher for mature IV product; formulation-dependent for oral product	High	Lower near term
Main commercial advantage	Oral option and established ALS use	Low cost and broad availability	Genetic targeting
Main commercial limitation	Administration cost and reimbursement complexity	Modest clinical effect and generic pricing	Small eligible population and specialized administration

Edaravone occupies an intermediate position: more differentiated than an old low-cost generic, but less genetically targeted than tofersen. Its value proposition depends on modest functional benefit, tolerability, access, and persistence.

What is the generic launch risk for edaravone?

Generic entry risk is asymmetric.

Intravenous Radicava

IV generic risk is relatively high because:

• The active ingredient is mature.
• The dosage form is established.
• Generic manufacturers may be able to develop an equivalent solution.
• Payers may favor lower-cost infusion products.

The main barriers are sterile manufacturing, quality systems, supply reliability, and potential product patents.

Radicava ORS

Oral suspension risk is more complex. A competitor must address:

• Active-ingredient equivalence.
• Suspension uniformity.
• Dose delivery through the supplied measuring device.
• Stability during storage and use.
• Taste and patient acceptability.
• Packaging and container compatibility.
• Any listed formulation or method-of-use patents.

A successful oral generic could have a greater commercial effect than IV generic entry because it would compete directly with the formulation designed to increase convenience and persistence.

What patent litigation and settlement agreements affect edaravone?

No major publicly established settlement or trial outcome had created a confirmed generic launch date for Radicava in the principal public record reviewed. The absence of a visible settlement does not establish freedom from challenge.

The most likely litigation triggers are:

1. An ANDA filing with Paragraph IV certifications.
2. A dispute over oral suspension formulation claims.
3. A challenge to method-of-use patents.
4. A dispute over whether a proposed label induces a patented use.
5. A patent-term or Orange Book listing dispute.

A settlement could permit an agreed future generic launch, an authorized generic arrangement, or a license under formulation patents. Such agreements can materially change expected revenue without invalidating the asserted patents.

What FDA regulatory factors shape the edaravone market?

FDA approval is only one part of commercialization. ALS products face significant access and evidence hurdles.

Coverage and utilization

Payers may require:

• Confirmed ALS diagnosis.
• Documentation of disease duration or functional status.
• Prescriber specialization.
• Prior authorization.
• Evidence of continued benefit.
• Site-of-care controls for IV therapy.

Oral suspension can reduce administrative and infusion costs, but its pharmacy benefit position may differ from the medical benefit position used for infused products.

Clinical positioning

The FDA label does not establish that edaravone reverses ALS or provides a cure. Its commercial positioning is based on slowing functional decline in an appropriate population. Physicians may weigh the magnitude of benefit against treatment burden, cost, disease progression, and patient preferences.

International regulation

Edaravone has a longer commercial history in Japan, where Radicut was approved before the U.S. launch. Regulatory labels, reimbursement, approved indications, and generic substitution rules differ by country. Geographic revenue is therefore not directly comparable across markets.

How strong is the edaravone patent estate?

The patent estate is moderate for a mature active ingredient and potentially stronger for the oral delivery system.

Factor	Assessment
Active ingredient protection	Weak or largely exhausted because edaravone is an established compound
IV product protection	Moderate, depending on current listed formulation patents
Oral suspension protection	Potentially stronger because formulation and delivery claims are newer
Method-of-use protection	Variable and vulnerable to label carving or validity challenges
Manufacturing know-how	Potentially meaningful, especially for oral suspension quality
Regulatory moat	Moderate, supported by clinical data, physician familiarity, and payer infrastructure
Biosimilar protection	Not relevant; edaravone is a small molecule, not a biologic

The commercial moat is therefore a combination of formulation know-how, regulatory history, brand recognition, distribution, reimbursement support, and patents. It is not based primarily on exclusive ownership of a novel chemical entity.

What revenue exposure does Mitsubishi Tanabe face?

Mitsubishi Tanabe’s exposure is concentrated in the ALS franchise. That concentration creates both operating leverage and risk.

Revenue upside comes from:

• Oral conversion.
• More patients receiving treatment.
• Longer treatment persistence.
• International expansion.
• Combination use with other ALS therapies.
• Improved access through home administration.

Revenue downside comes from:

• IV generic price erosion.
• Oral generic entry.
• Payer restrictions.
• Low treatment initiation rates.
• Clinical skepticism about incremental benefit.
• New ALS treatments that displace edaravone.
• Manufacturing interruptions or supply constraints.

The most important forecast variable is oral market penetration. A high-conversion scenario preserves the franchise but may shift revenue from IV to oral. A low-conversion scenario leaves Radicava dependent on infusion infrastructure and exposes it more directly to IV generic pressure.

What are the likely edaravone launch scenarios?

Scenario	Market outcome	Financial implication
Base case	Gradual oral adoption; stable ALS diagnosis; no immediate disruptive competitor	Flat to modest growth followed by maturity
Upside case	Higher oral conversion, better payer access, longer persistence	Sustained branded revenue growth
Downside case	IV generic launch followed by oral substitution; reimbursement pressure	Rapid price and share erosion
Disruption case	New broad-population ALS therapy with superior outcomes	Structural decline in edaravone demand

The most probable near-term pattern is a mature branded franchise with a route-of-administration shift, not a return to early-launch growth rates.

Key Takeaways

• Edaravone is marketed as Radicava in the United States and Radicut in Japan and other markets.
• The FDA approved IV Radicava in 2017 and Radicava ORS in 2022.
• The oral suspension is the main growth lever because it reduces infusion burden and may expand treatment access.
• The active ingredient is mature; remaining protection is more likely to depend on formulation, method-of-use, manufacturing, and regulatory factors.
• IV generic risk is higher than oral-suspension generic risk because oral suspension development is technically more complex.
• Tofersen competes only in SOD1 mutation-associated ALS, while riluzole remains the broad, lower-cost comparator.
• No confirmed major generic launch date or market-defining settlement is established in the public record reviewed.
• The financial trajectory is likely to move from launch growth to mature-franchise economics, with oral adoption determining the slope.

FAQs

Is edaravone a biologic or a small-molecule drug?

Edaravone is a small-molecule drug. Biosimilar rules do not apply. Competition proceeds through generic-drug pathways such as ANDAs.

Is Radicava ORS cheaper than intravenous Radicava?

The patient and payer economics depend on negotiated price, benefit classification, infusion costs, nursing services, and reimbursement. Oral administration can reduce administration expense even when the drug acquisition cost is not lower.

Can a generic manufacturer copy Radicava ORS?

A generic manufacturer may develop an equivalent oral suspension, but it must satisfy FDA requirements for pharmaceutical equivalence, bioequivalence, quality, stability, and device or dosing performance. Listed patents can also delay approval or launch.

Does edaravone extend survival in ALS?

The FDA approval is based on slowing functional decline in the studied population. Survival claims require separate evidence and should not be inferred from the approved functional endpoint. [1]

What is the largest commercial risk to edaravone?

The largest risk is a combination of generic entry and limited incremental patient uptake. IV generic competition could pressure price, while weak oral conversion would limit the franchise’s ability to offset that pressure.

References

1. U.S. Food and Drug Administration. (2024). Radicava and Radicava ORS prescribing information.
2. Centers for Disease Control and Prevention. (2022). Prevalence and incidence of amyotrophic lateral sclerosis in the United States. National ALS Registry.
3. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book.
4. U.S. Food and Drug Administration. (2024). Small business assistance: Frequently asked questions on the abbreviated new drug application process.
5. U.S. Food and Drug Administration. (2024). Patent certification and the 30-month stay under the Hatch-Waxman Amendments.
6. U.S. Food and Drug Administration. (2023). FDA grants accelerated approval to tofersen for SOD1 ALS.
7. Mitsubishi Tanabe Pharma Corporation. (2024). Integrated report and financial results materials.

DrugChatter Q&A for EDARAVONE

Edaravone market analysis 2025?